What is the average price of vancomycin exports from India?

The average unit price for vancomycin exports from India is $50.05 USD per unit, with prices ranging from $0.00 to $2697.42 depending on formulation, packaging, and order volume. The total market is valued at $92.2M across 3,071 shipments.

Which ports handle vancomycin exports from India?

The primary ports for vancomycin exports from India are SAHAR AIR (13.2% of shipments), SAHAR AIR CARGO ACC (INBOM4) (12.9% of shipments), NHAVA SHEVA SEA (INNSA1) (7.2% of shipments), DELHI AIR (4.4% of shipments), BANGALORE ACC (INBLR4) (4.4% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Why is India a leading exporter of vancomycin?

India is one of the world's leading exporters of vancomycin due to its large base of 318 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports vancomycin to 140 countries, demonstrating 72% global market coverage.

What certifications do Indian vancomycin exporters need?

Indian vancomycin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

How many buyers import vancomycin from India?

There are 743 registered buyers importing vancomycin from India, spread across 140 countries. The repeat buyer rate is 55.0%, indicating strong long-term trade relationships and consistent product quality.

What is the market share of the top vancomycin supplier from India?

MYLAN LABORATORIES LIMITED is the leading vancomycin exporter from India with a market share of 28.2% and total export value of $26.0M across 319 shipments. The top 5 suppliers together control 67.1% of total export value.

Vancomycin

India Pharmaceutical Trade Intelligence

$92.2M318 Suppliers140 CountriesHS 30042096

ExportsIndia → UNITED STATES54.8%India → GERMANY8.8%

ImportsCHINA → India$301.9K UNITED STATES → India$74.8K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: MYLAN INSTITUTIONAL

Vancomycin Export Data from India (2026) — Suppliers, Buyers & Trade Stats | TransData Nexus | TransData Nexus

How India Exports Vancomycin to the World

Q: Who are the top vancomycin exporters from India?

The top vancomycin exporters from India are: 1. MYLAN LABORATORIES LIMITED — $26.0M (28.2% market share); 2. STRIDES PHARMA SCIENCE LIMITED — $12.0M (13.1% market share); 3. GLAND PHARMA LIMITED — $11.1M (12.1% market share); 4. EUGIA PHARMA SPECIALITIES LIMITED — $7.0M (7.6% market share); 5. GLAND PHARMA LTD — $5.6M (6.1% market share). Together they account for 67.1% of India's total vancomycin export value.

Q: What is the total export value of vancomycin from India?

The total export value of vancomycin from India is $92.2M USD, recorded across 3,071 shipment transactions from 318 active exporters to 140 destination countries. The average shipment value is $30.0K.

Q: Which countries import vancomycin from India?

India exports vancomycin to 140 countries worldwide. The top importing countries are: UNITED STATES (54.8% share, $50.6M), GERMANY (8.8% share, $8.1M), AUSTRALIA (4.8% share, $4.4M), SAUDI ARABIA (2.9% share, $2.7M), ETHIOPIA (2.9% share, $2.6M). These five markets account for 74.2% of total export value.

Q: What is the HS code for vancomycin exports from India?

The primary HS code for vancomycin exports from India is 30042096. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Between 2022 and 2026, India exported $92.2M worth of vancomycin across 3,071 verified shipments to 140 countries — covering 72% of world markets in the Antibiotics segment. The largest destination is UNITED STATES (54.8%). MYLAN LABORATORIES LIMITED leads with a 28.2% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30042096

Vancomycin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Vancomycin export data snapshot — $92.2M · 318 exporters · 140 countriesTransData Nexus · Indian Customs Data

Top Vancomycin Exporters from India

318 active exporters · Ranked by export value

View all 318 →

Top Vancomycin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	MYLAN LABORATORIES LIMITED	$26.0M	319	3	28.2%
2	STRIDES PHARMA SCIENCE LIMITED

Top Countries Importing Vancomycin from India

140 destination markets · Ranked by import value

All 140 countries →

Top Countries Importing Vancomycin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$50.6M	54.8%
2	GERMANY	$8.1M	8.8%
3	AUSTRALIA	$4.4M	4.8%
4	SAUDI ARABIA	$2.7M	2.9%
5	ETHIOPIA	$2.6M	2.9%
6	DENMARK	$2.6M	2.8%
7	IRAQ	$1.7M	1.9%
8	PHILIPPINES	$1.6M	1.8%
9	THAILAND	$1.4M	1.5%
10	UNITED KINGDOM	$1.1M	1.2%

UNITED STATES is India's largest vancomycin export destination, absorbing 54.8% of total exports worth $50.6M. The top 5 importing countries — UNITED STATES, GERMANY, AUSTRALIA, SAUDI ARABIA, ETHIOPIA — together account for 74.2% of India's total vancomycin export value. The remaining 135 destination countries collectively receive the other 25.8%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Vancomycin to India?

15 origin countries · Total import value: $417.4K

India imports vancomycin from 15 countries with a combined import value of $417.4K. The largest supplier is CHINA ($301.9K, 11 shipments), followed by UNITED STATES and GERMANY. All values are from Indian Customs (DGFT) import records.

Countries Supplying Vancomycin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	CHINA	$301.9K	11	72.3%
2	UNITED STATES	$74.8K	74	17.9%
3	GERMANY	$8.4K	4	2.0%
4	AUSTRALIA	$7.7K	14	1.8%
5	CANADA	$5.2K	4	1.3%
6	UNITED ARAB EMIRATES	$4.6K	5	1.1%
7	LATVIA	$4.4K	2	1.0%
8	NETHERLANDS	$2.9K	2	0.7%
9	POLAND	$2.8K	2	0.7%
10	UNITED KINGDOM	$1.9K	1	0.5%

Showing top 10 of 15 origin countries

CHINA is the largest supplier of vancomycin to India, accounting for 72.3% of total import value. The top 5 origin countries — CHINA, UNITED STATES, GERMANY, AUSTRALIA, CANADA — together supply 95.4% of India's vancomycin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Vancomycin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, vancomycin is approved for various formulations, including intravenous and oral solutions. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for vancomycin, indicating a competitive generic market. Notably, on November 14, 2022, the FDA approved Alkem Laboratories Ltd.'s generic version of Firvanq, an oral vancomycin hydrochloride solution, in strengths of 25 mg/mL and 50 mg/mL. This approval underscores the FDA's commitment to expanding access to essential antibiotics.

Given the substantial number of Indian exporters (318) supplying vancomycin to the U.S., adherence to FDA regulations is paramount. Compliance with Current Good Manufacturing Practices (cGMP) and successful ANDA approvals are essential for market entry. Import alerts, which can arise from non-compliance, may significantly impact market access and should be diligently monitored.

2EU & UK Regulatory Framework

In the European Union, vancomycin is subject to the European Medicines Agency's (EMA) regulatory oversight. Marketing authorization requires compliance with the EMA's stringent guidelines, including adherence to Good Manufacturing Practice (GMP) standards. The EMA conducts periodic safety update report single assessments (PSUSAs) for vancomycin to ensure ongoing pharmacovigilance. For instance, in December 2025, the EMA published a PSUSA for vancomycin, resulting in variations to the product information to enhance safety measures. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of medicinal products. Post-Brexit, the UK has established its own regulatory framework, necessitating separate marketing authorizations for vancomycin. Compliance with UK-specific GMP requirements and pharmacovigilance obligations is essential for market access.

3WHO Essential Medicines & Global Standards

Vancomycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating severe bacterial infections. The 23rd edition of the list, updated in July 2023, continues to feature vancomycin, reflecting its enduring importance in global health. (test-cms.who.int) Additionally, vancomycin formulations are subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across markets.

4India Regulatory Classification

In India, vancomycin is classified as a Schedule H drug under the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Central Drugs Standard Control Organization (CDSCO) mandates that manufacturers obtain a No Objection Certificate (NOC) for the export of vancomycin formulations. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the ceiling price of vancomycin to ensure affordability; the latest revision was implemented in March 2025.

5Patent & Exclusivity Status

Vancomycin's primary patents have long expired, facilitating a robust generic market. However, secondary patents related to specific formulations or delivery methods may still be in effect. For example, in April 2025, a U.S. court ruled that Azurity Pharmaceuticals could not enforce its patent on a vancomycin liquid formulation against Alkem Laboratories Ltd., highlighting the complexities of patent litigation in the pharmaceutical sector.

6Recent Industry Developments

In December 2025, the EMA published a periodic safety update report single assessment (PSUSA) for vancomycin, leading to variations in product information to enhance safety measures. (ema.europa.eu)

In April 2025, a U.S. court ruled that Azurity Pharmaceuticals could not enforce its patent on a vancomycin liquid formulation against Alkem Laboratories Ltd., impacting the competitive landscape for vancomycin products.

In November 2022, the FDA approved Alkem Laboratories Ltd.'s generic version of Firvanq, an oral vancomycin hydrochloride solution, expanding treatment options for Clostridioides difficile infections.

In March 2025, the NPPA revised the ceiling price for vancomycin in India, reflecting efforts to balance affordability with industry sustainability.

In July 2023, the WHO updated its Model List of Essential Medicines, reaffirming vancomycin's status as a critical antibiotic for severe infections. (test-cms.who.int)

These developments underscore the dynamic regulatory and market environment surrounding vancomycin, necessitating continuous monitoring and compliance to ensure successful market participation.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Vancomycin

Retail & reference prices across 9 markets vs. India FOB export price of $50.05/unit

Global Price Benchmark for Vancomycin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	N/A	USD	Specific pricing information for Vancomycin 500 mg is not readily available from public U.S. government sources.
United Kingdom	N/A	GBP	Specific pricing information for Vancomycin 500 mg is not readily available from public UK government sources.
Germany	N/A	EUR	Specific pricing information for Vancomycin 500 mg is not readily available from public German government sources.
Australia	N/A

Supply Chain Risk Assessment — Vancomycin

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Vancomycin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the API sector. This dependency poses significant risks, as disruptions in Chinese supply chains can directly impact Indian pharmaceutical manufacturing.

In recent years, environmental regulations in China have led to the shutdown of numerous API manufacturers, causing supply disruptions and cost escalations. For instance, over the last year, nearly 1.5 lakh factories in China have closed down, of which a quarter will affect pharmaceuticals. Such events underscore the vulnerability of India's pharmaceutical supply chain due to its reliance on Chinese KSMs.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 67.1% of Vancomycin exports, with MYLAN LABORATORIES LIMITED alone contributing 28.2% ($26.0M). This high supplier concentration increases the risk of supply chain disruptions, as issues affecting these key players can have a disproportionate impact on global Vancomycin availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce import dependence. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for antibiotics production. While these initiatives are steps toward self-reliance, their impact on reducing supplier concentration in the Vancomycin supply chain remains to be seen.

Access Complete Vancomycin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 3,071 transactions across 140 markets.

Request Demo View Pricing

Frequently Asked Questions — Vancomycin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top vancomycin exporters from India?

The leading vancomycin exporters from India are MYLAN LABORATORIES LIMITED, STRIDES PHARMA SCIENCE LIMITED, GLAND PHARMA LIMITED, and 12 others. MYLAN LABORATORIES LIMITED leads with 28.2% market share ($26.0M). The top 5 suppliers together control 67.1% of total export value.

What is the total export value of vancomycin from India?

The total export value of vancomycin from India is $92.2M, recorded across 3,071 shipments from 318 active exporters to 140 countries. The average shipment value is $30.0K.

Which countries import vancomycin from India?

India exports vancomycin to 140 countries. The top importing countries are UNITED STATES (54.8%), GERMANY (8.8%), AUSTRALIA (4.8%), SAUDI ARABIA (2.9%), ETHIOPIA (2.9%), which together account for 74.2% of total export value.

What is the HS code for vancomycin exports from India?

The primary HS code for vancomycin exports from India is 30042096. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Vancomycin

Vancomycin

Top Vancomycin Exporters from India

Top Countries Importing Vancomycin from India

Who Supplies Vancomycin to India?

Quick Facts

Related Antibiotics

Related Analysis

Need Details?

Regulatory Landscape — Vancomycin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Vancomycin

Supply Chain Risk Assessment — Vancomycin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Vancomycin Trade Intelligence

Frequently Asked Questions — Vancomycin Exports from India

Who are the top vancomycin exporters from India?

What is the total export value of vancomycin from India?

Which countries import vancomycin from India?

What is the HS code for vancomycin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of vancomycin exports from India?

Which ports handle vancomycin exports from India?

Why is India a leading exporter of vancomycin?

What certifications do Indian vancomycin exporters need?

How many buyers import vancomycin from India?

What is the market share of the top vancomycin exporter from India?

Analysis Methodology